{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "This multicenter, non-randomized, single-arm trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "enrolled 101 patients with T1\u2013T4, N0, and M0 HNSCC"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Patients received 50 \u00b5g [ 99m Tc]tilmanocept radiolabeled with either 0.5 mCi (same day) or 2.0 mCi (next day)"
      },
      "Objective": {
        "score": 1,
        "evidence": "to determine the false negative rate (FNR) of sentinel lymph node biopsy (SLNB) relative to the pathologic nodal status"
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "FNR of sentinel lymph node biopsy (SLNB) relative to the pathologic nodal status"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "This multicenter, non-randomized, single-arm trial"
      },
      "Blinding": {
        "score": 3,
        "evidence": "open-label"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "81 of 83 patients (97.6 %)"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "yielding an FNR of 2.56 %; NPV was 97.8 % and overall accuracy was 98.8 %"
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "ClinicalTrials.gov identifier NCT00911326"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 14,
    "max_score": 25
  },
  "model": "gpt-4o"
}